Thrombocytosis and thrombocythemia

Blood Reviews

Volumn 15, Issue 4, 2001, Pages 159-166

  Schafer, A I ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiplatelet therapy; Clonality; Cytoreduction; Essential thrombocythemia; Familial thrombocytosis; Megakaryocytopoiesis; Myeloproliferative disorders; Reactive thrombocytosis; Thrombopoietin; Thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; THROMBOPOIETIN;

BLEEDING; BRAIN ISCHEMIA; BUDD CHIARI SYNDROME; CLINICAL FEATURE; ERYTHROMELALGIA; HUMAN; INTRAUTERINE GROWTH RETARDATION; MEGAKARYOPOIESIS; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; THROMBOCYTHEMIA; THROMBOCYTOSIS;

EID: 0035735611     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2001.0162     Document Type: Article

References (91)

1. Occurrence, etiology, and clinical significance of extreme thrombocytosis: A study of 280 cases
2. Blood thrombopoietin levels in clonal thrombocytosis
3. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis
4. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene
5. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia
6. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA
7. Measurement of thrombopoietic levels: Clinical and biological relationships
8. Hereditary thrombocythaemia is a genetically heterogeneous disorder: Exclusion of TPO and MPL in two families with hereditary thrombocythaemia
9. Familial thrombocytosis as a recessive, possibly X-linked trait in an Arab family
10. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976-1995
11. Recent progress in the pathogenesis and management of essential thrombocythemia
12. Thrombocytosis and essential thrombocythemia
13. Essential thrombocythaemia in children
14. Essential thrombocythaemia in children: A recent report of nine cases
15. Thrombopoietin
16. Plasma thrombopoietin levels in thrombocytopenic states: Implication for a regulatory role of bone marrow megakaryocytes
17. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization
18. Thrombopoietin measurement in thrombocytosis: Dysregulation and lack of feedback inhibition in essential thrombocythaemia
19. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis
20. High levels of thrombopoietin in sera of patients with essential thrombocythemia: Cause or consequence of abnormal platelet production
21. Stong inverse correlation between serum TPO level and platelet count in essential thrombocythemia
22. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia
23. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: Immunoperoxidase staining patterns and clinical correlates
24. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera
25. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis
26. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MDGF) in essential thrombocythemia
27. Selective hypersensitivity to granulocyte-macrophage-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors
28. Circulating erythroid progenitors in polycythemia vera are hypersensitive to IGF-I in vitro: Studies in an improved serum-free medium
29. Megakaryocyte and erythroid colony formation in essential thrombocythemia and reactive thrombocytosis: Diagnostic value and correlation to complications
30. The determination of spontaneous megakaryocyte colony formation in an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis
31. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
32. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors
33. The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease
34. Clonal analysis of myeloproliferative disorders using X-linked DNA polymorphisms
35. Clonality analysis of hematopoiesis in essential thrombocythaemia: Advantages of studying T lymphocytes and platelets
36. Clonal heamopoiesis in normal elderly women: Implications for the myeloproliferative disorders and myelodysplastic syndromes
37. A novel clonality assay based on transcriptional analysis of the active X chromosome
38. Bunn HF Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction
39. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
40. Essential thrombocythemia: Another 'heterogeneous disease' better understood?
41. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia
42. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group
43. Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients
44. BCR-ABL transcripts detectable in all myeloproliferative states
45. BCR-ABL rearrangement is not detectable in essential thrombocythemia
46. Patients with essential thrombocythemia do not express BCR-ABL transcripts
47. Absence of bcr/abl rearrangement in 41 patients with essential thrombocythemia
48. Bleeding and thrombosis in the myeloproliferative disorders
49. Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: Current concepts and perspectives
50. Bleeding and thrombosis in myeloproliferative disorders: Mechanisms and treatment
51. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia
52. Clinical spectrum, investigations and treatment of Budd-Chiari syndrome
53. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Bedd-Chiari syndrome or portal vein thrombosis
54. Neurologic and visual symptoms in essential thrombocythemia: Efficacy of low-does aspirin
55. Neurological complications of essential thrombocytosis (ET)
56. Erythromelalgia: A pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera
57. Platelet consumption in thrombocythemia complicated by erythromelalgia: Reversal by aspirin
58. A single institutional experience with 43 pregnancies in essential thrombocythemia
59. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause
60. A long-term retrospective study of young women with essential thrombocythemia
61. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
62. Essential thrombocythemia
63. Acquired von Willebrand disease in patients with high platelet counts
64. Cardiac involvement in patients with myeloproliferative disorders
65. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
66. Stem cell plasticity in muscle and bone marrow
67. Endothelial progenitor cells for regeneration
68. Donor origin of circulating endothelial progenitors after allogeneic bone marrow transplantation
69. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells
70. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis
71. Management of thrombocythemia
72. A clinical update in polycythemia vera and essential thrombocythemia
73. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
74. Clinical parameters for determining when and when not to treat essential thrombocythemia
75. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors
76. Clinical course of essential thrombocythemia in 147 cases
77. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukemic transformation and review of the literature
78. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications
79. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial
80. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
81. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
82. Acquired DNA mutations associated with in vivo hydroxyurea exposure
83. The effects of anagrelide on human megakaryocytopoiesis
84. Anagrelide, a therapy for thrombocythemia states: Experience in 577 patients
85. Long-term use of anagrelide in young patients with essential thrombocythemia
86. Haemopoitic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia
87. Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo
88. Increased thromboxane biosynthesis in essential thrombocythemia
89. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera
90. Aspirin and risk of bleeding in patients with thrombocythemia
91. European Collaboration on Low-dose Aspirin in Polycythemia (ECLAP): A randomized trial